Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of OKG-0301 for acute adenoviral conjunctivitis
ACTRN12619000177156Phase 2Recruiting
- Sponsor
- Okogen
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ranpirnase in adenoviral conjunctivitis, viral conjunctivitis and infectious conjunctivitis (3 arms), sponsored by Okogen. Primary endpoint: Mean change from baseline in viral titre levels in the study eye. Started Feb 2019; status: recruiting.
02
Drugs
ranpirnase
03
Conditions
adenoviral conjunctivitisviral conjunctivitisinfectious conjunctivitis
Beyond the preview
Go deeper on ACTRN12619000177156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000177156.